title: pdFVIII/VWF may be an alternative treatment for old medical patient with acquired haemophilia A and systemic vascular disease?
abstract: Acquired Haemophilia is a severe, rare and potentially life-threatening bleeding that affects both males and females with an incidence of 1.5 cases/million/year. Mucocutaneous haemorrhages or haematomas are the typical expression of this disease as a consequence of a decrease in FVIII activity and the presence of a FVIII inhibitor, which differs from congenital haemophilia. We report a case of a 71 year-old-man who presented with spontaneous haematomas and severe anaemia and suffered from vascular disease. At admission, all haemostatic and laboratory data were diagnostic for idiopathic AHA. Treatment with by-passing agents such as rFVIIa was contraindicated because of the risk of thromboembolic events. Despite the fact that administration of FVIII concentrates in AHA is recommended only in patients with an inhibitor titre<5.0 BU, the physicians decided to use pdFVIII/vWF with corticosteroids in this patient. One month later, the FVIII was within the normal range and the inhibitors had disappeared. In our case, pdFVIII/vWF resulted in a safe and effective alternative for the treatment of acquired haemophilia A in a patient at high thromboembolic risk.
authors.affiliation: Center for Hemorrhagic and Thrombotic Diseases, University Hospital of Udine, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Barillari
authors.forename: Samantha
authors.initials: S
authors.lastname: Pasca
mesh_terms: D000368:Aged; D015942:Factor VIIa / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D014652:Vascular Diseases / Q000188:drug therapy*; D014841:von Willebrand Factor / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D014841:von Willebrand Factor; C103587:recombinant FVIIa; D015942:Factor VIIa